Study identifier:D5890C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open, phase III, multicentre, 52-week study, evaluating the safety and efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg twice daily) in Japanese patients with asthma
asthma
Phase 3
No
Budesonide/Formoterol
All
120
Interventional
16 Years +
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This study is to confirm the safety of Symbicort® Turbuhaler® 160/4.5 µg 1, 2 or 4 inhalation b.i.d. over a 52 week treatment period in asthmatic patients who are being treated with IGCS and long acting β2-agonist (LABA) and/or other anti-asthmatic drugs.
Location
Location
Komaki, Aichi, Japan
Location
Seto, Aichi, Japan
Location
Gifu, Gifu, Japan
Location
Ora, Gunma, Japan
Location
Hiroshima, Hiroshima, Japan
Location
Sapporo, Hokkaido, Japan
Location
Tomakomai, Hokkaido, Japan
Location
Morioka, Iwate, Japan
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.